RNA Metabolism Dysregulation in 4R-Tauopathies

RNA Metabolism Dysregulation in 4R-Tauopathies

Introduction

The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated 4-repeat (4R) tau protein, including [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration), [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease), [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy), and [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)](/genes/mapt). While tau pathology is the hallmark of these disorders, emerging evidence demonstrates that RNA metabolism dysregulation plays a critical pathogenic role, with RNA-binding proteins (RBPs) such as TDP-43, FUS, and heterogeneous nuclear ribonucleoproteins (hnRNPs) contributing to disease progression[@baker2021][@dormann2021].

This pathway model maps the complete landscape of RNA metabolism dysfunction in 4R-tauopathies, examining splicing alterations, RNA granule formation, translational dysregulation, and shared mechanisms with TDP-43 proteinopathies in [Amyotrophic Lateral Sclerosis (ALS)](/mechanisms/als-tdp43-pathway) and [Frontotemporal Dementia (FTD)](/mechanisms/ftd-tdp43-pathway).

RNA-Binding Proteins in 4R-Tauopathies

TDP-43 (TAR DNA-Binding Protein 43)

RNA Metabolism Dysregulation in 4R-Tauopathies

Introduction

The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated 4-repeat (4R) tau protein, including [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration), [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease), [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy), and [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)](/genes/mapt). While tau pathology is the hallmark of these disorders, emerging evidence demonstrates that RNA metabolism dysregulation plays a critical pathogenic role, with RNA-binding proteins (RBPs) such as TDP-43, FUS, and heterogeneous nuclear ribonucleoproteins (hnRNPs) contributing to disease progression[@baker2021][@dormann2021].

This pathway model maps the complete landscape of RNA metabolism dysfunction in 4R-tauopathies, examining splicing alterations, RNA granule formation, translational dysregulation, and shared mechanisms with TDP-43 proteinopathies in [Amyotrophic Lateral Sclerosis (ALS)](/mechanisms/als-tdp43-pathway) and [Frontotemporal Dementia (FTD)](/mechanisms/ftd-tdp43-pathway).

RNA-Binding Proteins in 4R-Tauopathies

TDP-43 (TAR DNA-Binding Protein 43)

TDP-43 is a nuclear DNA/RNA-binding protein encoded by the [TARDBP](/genes/tardbp) gene, involved in multiple RNA processing functions including transcription regulation, alternative splicing, RNA transport, and stability[@baker2021]. In healthy neurons, TDP-43 predominantly localizes to the nucleus, but in disease states it mislocalizes to the cytoplasm where it forms inclusion bodies.

TDP-43 Pathology in 4R-Tauopathies

| Disease | TDP-43 Inclusions | Frequency | Reference |
|---------|-------------------|-----------|-----------|
| PSP | Neuronal and glial cytoplasmic inclusions | 10-30% | [@baker2021tdp] |
| CBD | Motor cortex and basal ganglia | 20-40% | [@koga2017tdp] |
| AGD | Limbic system, amygdala | 15-25% | [@yokota2020tdp] |
| GGT | White matter, oligodendrocytes | 5-15% | [@ahmed2013ggt] |
| FTDP-17 | Frontal cortex, brainstem | Variable | [@zheng2022tdp] |

Pathogenic mechanisms:

FUS (Fused in Sarcoma)

FUS is another DNA/RNA-binding protein involved in transcription, RNA splicing, transport, and translation[@dormann2021]. Pathogenic FUS mutations cause familial ALS and FTD, but FUS pathology is also observed in 4R-tauopathies.

FUS in 4R-Tauopathies

• PSP: Moderate FUS pathology in 15-20% of cases, particularly in the subthalamic nucleus and brainstem[@ahmed2013]
• CBD: FUS-positive inclusions in 10-25% of cases, often co-localizing with tau
• AGD: Less common FUS involvement compared to TDP-43
• GGT: Rare FUS pathology

• In 4R-tauopathies, FUS inclusions typically lack the characteristic FUS mutations seen in ALS
• Co-localization with 4R tau suggests a shared pathogenic mechanism rather than primary FUS disease

hnRNPs (Heterogeneous Nuclear Ribonucleoproteins)

The hnRNP family includes over 20 proteins (hnRNPA1, hnRNPA2B1, hnRNPK, hnRNPL, hnRNPU, etc.) that regulate RNA splicing, stability, transport, and translation[@jeanmarc2022].

hnRNP Dysregulation in 4R-Tauopathies

| hnRNP | Function | Dysregulation in 4R-Tauopathies |
|-------|----------|--------------------------------|
| [hnRNPA1](/proteins/hnrnp-a1-protein) | Splicing regulation, stress granule formation | Aggregate formation in PSP and CBD |
| [hnRNPA2B1](/proteins/hnrnpa2b1-protein) | RNA splicing, transport | Mutations cause multisystem proteinopathy |
| [HNRNPK](/proteins/hnrnpk-protein) | Transcription, RNA processing | Altered expression in CBD |
| hnRNPL | Alternative splicing | Dysregulated in PSP |

Alternative Splicing Alterations

Tau Exon 10 Splicing

The MAPT gene produces six tau isoforms through alternative splicing of exons 2, 3, and 10. Exclusion of exon 10 produces 3R tau, while inclusion produces 4R tau. In 4R-tauopathies, there is a selective increase in 4R tau isoforms[@wang2024].

Splicing regulators affected:

• SR proteins: Altered phosphorylation and distribution
• hnRNPs: hnRNPA1 and hnRNPG modulate exon 10 inclusion
• TIA1: Stress granule protein that influences splicing

Cryptic Exon Splicing

TDP-43 depletion leads to the inclusion of cryptic exons in multiple transcripts [@ling2025]:

• STMN2 — Cryptic exon inclusion causes loss of function in axon regeneration
• UNC13A — Cryptic splicing contributes to ALS/FTD pathogenesis
• TDP-43 regulated transcripts — Affected in both ALS/FTD and 4R-tauopathies

Disease-Specific Splicing Signatures

| Disease | Key Splicing Alterations | Reference |
|---------|-------------------------|-----------|
| PSP | Aberrant splicing of neuronal transcripts, MAPT splice variants | [@lawton2012psp] |
| CBD | Splicing changes in cytoskeletal, synaptic genes | [@koga2018cbd] |
| AGD | Limbic system splicing alterations | [@mithihara2019agd] |

RNA Granule Formation

Stress Granules

Stress granules (SGs) are cytoplasmic RNA-protein aggregates formed under stress conditions (oxidative stress, heat shock, viral infection) to stall translation and protect mRNAs [@wolozin2022]. They contain:

• Translation initiation factors (eIF3, eIF4E)
• RNA-binding proteins (TIA1, TIA1L, G3BP1)
• 40S ribosomal subunits
• mRNAs

Stress Granule Pathology in 4R-Tauopathies

| Feature | PSP | CBD | AGD | GGT |
|---------|-----|-----|-----|-----|
| TIA1-positive SGs | ++ | ++ | + | + |
| G3BP1-positive SGs | ++ | ++ | + | + |
| Co-localization with tau | Yes | Yes | Rare | Yes |

Pathogenic cascade:

Processing Bodies (P-bodies)

P-bodies are cytoplasmic foci involved in mRNA decay and storage. Unlike stress granules, they are present constitutively and increase under specific conditions [@standart2024].

• DCP1A/DCP2: Decapping complex components
• GW182: miRNA-mediated silencing
• XRN1: 5'-3' exoribonuclease

• Reduced mRNA decay
• Accumulation of defective mRNAs
• Dysregulated miRNA function

RNA Granule Dysfunction Model

Translational Dysregulation

Global Translation Impairment

4R-tauopathies exhibit widespread translational dysregulation:

Specific Translation Targets

| Target | Function | Dysregulation | Consequence |
|--------|----------|---------------|-------------|
| Synaptic proteins | Neurotransmission | Reduced synthesis | Synaptic dysfunction |
| Mitochondrial proteins | Energy metabolism | Impaired translation | Energy failure |
| Cytoskeletal proteins | Structure | Altered expression | Axonal transport defects |

Ribostasis Failure

The concept of "ribostasis" refers to the proper balance of ribosome biogenesis, translation, and mRNA decay [@hetauer2023]. In 4R-tauopathies:

• Ribosome biogenesis is impaired in the nucleolus
• rRNA processing shows age-related decline
• tRNA metabolism is dysregulated

Comparison with TDP-43 Proteinopathies (ALS/FTD)

Shared Mechanisms

| Mechanism | 4R-Tauopathies | ALS/FTD | Shared? |
|-----------|----------------|---------|---------|
| TDP-43 aggregation | + | +++ | Yes |
| Stress granule formation | ++ | +++ | Yes |
| Nuclear import defects | + | +++ | Yes |
| Cryptic exon splicing | + | +++ | Yes |
| FUS pathology | + | +++ | Partial |
| hnRNP dysfunction | ++ | +++ | Yes |

Key Differences

Convergent Pathways

Therapeutic Implications

RNA-Targeting Strategies

• Target MAPT mRNA to reduce tau production
• [NIO752](/clinical-trials/nio752-psp) — Tau ASO in PSP trials
• ASOs targeting TDP-43 for ALS/FTD

• Ribavirin: Inhibits stress granule formation
• MSU-420: TDP-43 aggregation inhibitor

• AAV-delivered shRNA against toxic transcripts
• CRISPR-based approaches to correct splicing

Restoration of RNA Metabolism

| Target | Approach | Stage | Reference |
|--------|----------|-------|-----------|
| TDP-43 nuclear import | Small molecule enhancers | Preclinical | [@neefjes2021] |
| Stress granule clearance | Autophagy modulators | Preclinical | [@wedge2021] |
| Splicing correction | ASO-mediated | Clinical (ALS) | [@corti2022] |

Cross-References

• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [FUS Proteinopathy](/mechanisms/fus-proteinopathy)
• [RNA Granule Dysfunction](/mechanisms/rna-granule-dysfunction-neurodegeneration)
• [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granule-rna-granules)
• [ALS RNA Metabolism](/mechanisms/als-rna-metabolism-and-proteostasis-failure)
• [PSP Pathway](/mechanisms/psp-pathway)
• [CBD Pathway](/mechanisms/cbd-pathway)
• [hnRNPA1 Protein](/proteins/hnrnp-a1-protein)
• [hnRNPA2B1 Protein](/proteins/hnrnpa2b1-protein)
• [TDP-43 Protein](/proteins/tdp-43-protein)
• [FUS Protein](/proteins/fus-protein)

See Also

• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy)
• [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)](/genes/mapt)
• [Amyotrophic Lateral Sclerosis (ALS)](/mechanisms/als-tdp43-pathway)
• [Frontotemporal Dementia (FTD)](/mechanisms/ftd-tdp43-pathway)
• [TARDBP](/genes/tardbp)
• [hnRNPA1](/proteins/hnrnp-a1-protein)
• [hnRNPA2B1](/proteins/hnrnpa2b1-protein)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References